Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epigenetic approach to early-onset Parkinson's disease: low methylation status of SNCA and PARK2 promoter regions.
Eryilmaz IE, Cecener G, Erer S, Egeli U, Tunca B, Zarifoglu M, Elibol B, Bora Tokcaer A, Saka E, Demirkiran M, Akbostanci C, Dogu O, Colakoglu B, Kenangil G, Kaleagasi H. Eryilmaz IE, et al. Among authors: demirkiran m. Neurol Res. 2017 Nov;39(11):965-972. doi: 10.1080/01616412.2017.1368141. Epub 2017 Aug 22. Neurol Res. 2017. PMID: 28830306
Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease.
Eryilmaz IE, Erer S, Zarifoglu M, Egeli U, Karakus E, Yurdacan B, Cecener G, Tunca B, Colakoglu B, Bora Tokcaer A, Saka E, Demirkiran M, Akbostanci C, Dogu O, Kaleagasi H, Kenangil G, Cakmur R, Elibol B. Eryilmaz IE, et al. Among authors: demirkiran m. Clin Neurol Neurosurg. 2020 Dec;199:106257. doi: 10.1016/j.clineuro.2020.106257. Epub 2020 Oct 1. Clin Neurol Neurosurg. 2020. PMID: 33039854
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C, Ozakbas S, Terzi M, Karabudak R, Sevim S, Turkoglu R, Soysal A, Balcı BP, Efendi H, Turan ÖF, Yüceyar N, Yetkin MF, Karahan SZ, Demirkıran M, Guler S, Agan K, Kıylıoğlu N, Baba C, Tuncer A, Köseoğlu M. Boz C, et al. Among authors: demirkiran m. Neurol Sci. 2023 Jun;44(6):2121-2129. doi: 10.1007/s10072-023-06608-z. Epub 2023 Jan 23. Neurol Sci. 2023. PMID: 36689010
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S. Boz C, et al. Among authors: demirkiran m. Mult Scler Relat Disord. 2019 Nov;36:101376. doi: 10.1016/j.msard.2019.101376. Epub 2019 Aug 26. Mult Scler Relat Disord. 2019. PMID: 31473488
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sen S, Tuncer A, Ozakbas S, Uzunkopru C, Baba C, Demir S, Beckmann Y, Gumus H, Arslan G, Kilic AK, Altintas A, Yuceyar N, Turan OF, Tutuncu M, Terzi M, Acar P, Bunul SD, Balci BP, Bir LS, Koseoglu M, Mungan S, Gunduz T, Dogan IG, Kotan D, Uygunoglu U, Ekmekci O, Demirkiran M, Kamisli O, Kabay SC, Tamam Y, Omerhoca S, Sevim S, Guler S, Kurtuncu M, Efendi H, Karabudak R, Siva A. Sen S, et al. Among authors: demirkiran m. Mult Scler Relat Disord. 2022 Feb;58:103399. doi: 10.1016/j.msard.2021.103399. Epub 2021 Nov 19. Mult Scler Relat Disord. 2022. PMID: 35216782 Free PMC article.
Rare onset symptoms in multiple sclerosis.
Evlice A, Demir T, Kaleağası C, Özcan F, Demirkıran M. Evlice A, et al. Among authors: demirkiran m. Acta Clin Belg. 2016 Jun;71(3):154-7. doi: 10.1080/17843286.2016.1147675. Epub 2016 Apr 21. Acta Clin Belg. 2016. PMID: 27098603
41 results